Goldman Sachs’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.4M | Sell |
934,668
-212,634
| -19% | -$6.91M | ﹤0.01% | 1471 |
|
|
2025
Q1 | $43.3M | Sell |
1,147,302
-1,982,302
| -63% | -$74.9M | 0.01% | 1145 |
|
|
2024
Q4 | $256M | Buy |
3,129,604
+2,180,353
| +230% | +$178M | 0.04% | 355 |
|
|
2024
Q3 | $108M | Buy |
949,251
+212,512
| +29% | +$24.3M | 0.02% | 645 |
|
|
2024
Q2 | $55.6M | Buy |
736,739
+38,247
| +5% | +$2.89M | 0.01% | 942 |
|
|
2024
Q1 | $47.7M | Buy |
698,492
+217,373
| +45% | +$14.8M | 0.01% | 1014 |
|
|
2023
Q4 | $30.2M | Buy |
481,119
+52,005
| +12% | +$3.27M | 0.01% | 1276 |
|
|
2023
Q3 | $21.9M | Sell |
429,114
-16,731
| -4% | -$853K | ﹤0.01% | 1436 |
|
|
2023
Q2 | $22.3M | Sell |
445,845
-52,506
| -11% | -$2.62M | ﹤0.01% | 1476 |
|
|
2023
Q1 | $18.7M | Buy |
498,351
+98,987
| +25% | +$3.71M | ﹤0.01% | 1566 |
|
|
2022
Q4 | $19.1M | Sell |
399,364
-88,519
| -18% | -$4.24M | ﹤0.01% | 1661 |
|
|
2022
Q3 | $11.7M | Buy |
487,883
+134,502
| +38% | +$3.23M | ﹤0.01% | 2012 |
|
|
2022
Q2 | $7.69M | Buy |
353,381
+10,830
| +3% | +$236K | ﹤0.01% | 2338 |
|
|
2022
Q1 | $8.27M | Buy |
342,551
+144,074
| +73% | +$3.48M | ﹤0.01% | 2396 |
|
|
2021
Q4 | $4.72M | Sell |
198,477
-47,817
| -19% | -$1.14M | ﹤0.01% | 2847 |
|
|
2021
Q3 | $6.25M | Buy |
246,294
+60,709
| +33% | +$1.54M | ﹤0.01% | 2628 |
|
|
2021
Q2 | $4.18M | Buy |
185,585
+4,485
| +2% | +$101K | ﹤0.01% | 2915 |
|
|
2021
Q1 | $3.58M | Sell |
181,100
-114,808
| -39% | -$2.27M | ﹤0.01% | 2916 |
|
|
2020
Q4 | $7.86M | Buy |
+295,908
| New | +$7.86M | ﹤0.01% | 2197 |
|
|
2020
Q3 | – | Sell |
-87,424
| Closed | -$2.76M | – | 4535 |
|
|
2020
Q2 | $2.76M | Buy |
+87,424
| New | +$2.76M | ﹤0.01% | 2670 |
|